| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2017-11-16 23:01:43 UTC |
|---|
| Update Date | 2022-03-07 03:18:13 UTC |
|---|
| HMDB ID | HMDB0240216 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | Lafutidine |
|---|
| Description | Lafutidine, also known as protecadin, belongs to the class of organic compounds known as alkyl aryl ethers. These are organic compounds containing the alkyl aryl ether functional group with the generic formula R-O-R' , where R is an alkyl group and R' is an aryl group. In humans, lafutidine is involved in the lafutidine h2-antihistamine action pathway. Lafutidine is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review a significant number of articles have been published on Lafutidine. |
|---|
| Structure | O=C(CS(=O)CC1=CC=CO1)NC\C=C/COC1=NC=CC(CN2CCCCC2)=C1 InChI=1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2- |
|---|
| Synonyms | | Value | Source |
|---|
| Protecadin | Kegg | | (+)-2-[(2-Furanylmethyl)sulfinyl]-N-[(2Z)-4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]-2-butenyl]-acetamide | HMDB | | (Z)-(+)-2-[(2-Furanylmethyl)sulfinyl]-N-[4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]-2-butenyl]-acetamide | HMDB | | (+)-2-[(2-Furanylmethyl)sulfinyl]-N-[(2Z)-4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]-2-buten-1-yl]acetamide | HMDB | | (+)-2-(Furfurylsulfinyl)-N-[(Z)-4-[[4-(piperidinomethyl)-2-pyridyl]oxy]-2-butenyl]acetamide | HMDB | | (+)-Lafutidine | HMDB | | FRG 8813 | HMDB | | Laflutidine | HMDB | | Lafukem | HMDB | | Stogar | HMDB | | Lafutidine | HMDB, MeSH | | 2-(Furan-2-ylmethylsulphinyl)-N-[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide | Generator, HMDB | | N-(4-(4-Piperidinylmethyl)pyridyl-2-oxy)-(Z)-butenyl-2-(furfurylsulfinyl)acetamide | MeSH, HMDB | | N-(4-(4-Piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide | MeSH, HMDB |
|
|---|
| Chemical Formula | C22H29N3O4S |
|---|
| Average Molecular Weight | 431.55 |
|---|
| Monoisotopic Molecular Weight | 431.1878776 |
|---|
| IUPAC Name | 2-[(furan-2-yl)methanesulfinyl]-N-[(2Z)-4-({4-[(piperidin-1-yl)methyl]pyridin-2-yl}oxy)but-2-en-1-yl]acetamide |
|---|
| Traditional Name | lafutidine |
|---|
| CAS Registry Number | 118288-08-7 |
|---|
| SMILES | O=C(CS(=O)CC1=CC=CO1)NC\C=C/COC1=NC=CC(CN2CCCCC2)=C1 |
|---|
| InChI Identifier | InChI=1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2- |
|---|
| InChI Key | KMZQAVXSMUKBPD-DJWKRKHSSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as alkyl aryl ethers. These are organic compounds containing the alkyl aryl ether functional group with the generic formula R-O-R' , where R is an alkyl group and R' is an aryl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic oxygen compounds |
|---|
| Class | Organooxygen compounds |
|---|
| Sub Class | Ethers |
|---|
| Direct Parent | Alkyl aryl ethers |
|---|
| Alternative Parents | |
|---|
| Substituents | - Alkyl aryl ether
- Aralkylamine
- Piperidine
- Pyridine
- Furan
- Heteroaromatic compound
- Amino acid or derivatives
- Carboxamide group
- Secondary carboxylic acid amide
- Sulfoxide
- Tertiary aliphatic amine
- Tertiary amine
- Carboxylic acid derivative
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Sulfinyl compound
- Organonitrogen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Organic oxide
- Organosulfur compound
- Amine
- Organopnictogen compound
- Carbonyl group
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.45 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.7055 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.2 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 917.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 166.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 167.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 164.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 94.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 262.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 331.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 619.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 782.8 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 130.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 835.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 234.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 254.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 527.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 329.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 16.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Lafutidine,1TMS,isomer #1 | C[Si](C)(C)N(C/C=C\COC1=CC(CN2CCCCC2)=CC=N1)C(=O)CS(=O)CC1=CC=CO1 | 3540.1 | Semi standard non polar | 33892256 | | Lafutidine,1TMS,isomer #1 | C[Si](C)(C)N(C/C=C\COC1=CC(CN2CCCCC2)=CC=N1)C(=O)CS(=O)CC1=CC=CO1 | 3343.2 | Standard non polar | 33892256 | | Lafutidine,1TMS,isomer #1 | C[Si](C)(C)N(C/C=C\COC1=CC(CN2CCCCC2)=CC=N1)C(=O)CS(=O)CC1=CC=CO1 | 4388.7 | Standard polar | 33892256 | | Lafutidine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C/C=C\COC1=CC(CN2CCCCC2)=CC=N1)C(=O)CS(=O)CC1=CC=CO1 | 3713.6 | Semi standard non polar | 33892256 | | Lafutidine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C/C=C\COC1=CC(CN2CCCCC2)=CC=N1)C(=O)CS(=O)CC1=CC=CO1 | 3454.0 | Standard non polar | 33892256 | | Lafutidine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C/C=C\COC1=CC(CN2CCCCC2)=CC=N1)C(=O)CS(=O)CC1=CC=CO1 | 4425.2 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Lafutidine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Lafutidine LC-ESI-qTof , Positive-QTOF | splash10-00di-0319500000-21e5d3163103c305767b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lafutidine , positive-QTOF | splash10-0uec-0629700000-2cad78fc15f4386b3645 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lafutidine , positive-QTOF | splash10-00di-0319500000-21e5d3163103c305767b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 10V, Positive-QTOF | splash10-01qa-1676900000-3adc00bef17a159fb17e | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 20V, Positive-QTOF | splash10-03fu-2971000000-7ee0ab341e67b0ccb95d | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 40V, Positive-QTOF | splash10-01t9-4930000000-1265ca526856cae249ff | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 10V, Negative-QTOF | splash10-001i-1930700000-aec8e386acbf098257aa | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 20V, Negative-QTOF | splash10-0059-2920100000-149ac7afce52861c0b08 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 40V, Negative-QTOF | splash10-0016-6900000000-695b1fd2b230388122f4 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 10V, Positive-QTOF | splash10-001i-1015900000-d484d58eb169f3ec6743 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 20V, Positive-QTOF | splash10-01q9-9453800000-eb9c012110cbed695f73 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 40V, Positive-QTOF | splash10-001m-9400000000-c87dcefee5d75f368da0 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 10V, Negative-QTOF | splash10-001i-1301900000-6c348a77d8546c865e4c | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 20V, Negative-QTOF | splash10-01ox-5902100000-f69667109b92c6667827 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lafutidine 40V, Negative-QTOF | splash10-0h36-9711000000-19ce75902d45bf2db889 | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Shimatani T, Inoue M, Kuroiwa T, Xu J, Nakamura M, Tazuma S, Ikawa K, Morikawa N: Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine. Dig Dis Sci. 2006 Jan;51(1):114-20. [PubMed:16416222 ]
|
|---|